CLL drug venetoclax under the microscope: genetic clues may improve treatment

NCT ID NCT03986034

Recruiting now Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tracks genetic changes in chronic lymphocytic leukemia (CLL) cells during treatment with the drug venetoclax. Researchers aim to understand how the cancer evolves as the drug is started. 75 adults with relapsed or refractory CLL will receive venetoclax and undergo regular blood tests, CT scans, and bone marrow biopsies over at least 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax
What this could lead to: If successful, this could help doctors understand why some CLL patients respond better to venetoclax and guide more personalized treatment.
What could go wrong: This is a small, early-phase study focused on understanding genetic changes, not on proving a new treatment works. Results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.